Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somapacitan PK of 5 mg/1.5 mL vs 10 mg/1.5 mL
NCT03905850Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2019
- Primary completion
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of somapacitan in growth hormone deficiency (GHD) (3 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the somapacitan serum concentration time curve from time 0 to the time of the last quantifiable concentration and Maximum serum concentration of somapacitan. Started Mar 2019; status: completed.
02
Drugs
somapacitan
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT03905850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03905850.